Akebia Therapeutics vs CorMedix
AKBA and CRMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AKBA and CRMD compare
CorMedix is the larger company, worth 3.3 times as much as Akebia Therapeutics ($364M against $111M).
CorMedix grew revenue faster over the last twelve months (281% versus 7.5% for Akebia Therapeutics).
CorMedix keeps more of each dollar of sales as profit, with a net margin of 40.5% compared with −13.5% at Akebia Therapeutics.
CorMedix scores higher on the StockData Score (13 against 6 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AKBA | CRMD |
|---|---|---|
| Size and price | ||
| Market cap | $111M | $364M |
| Share price | $0.400 | $4.67 |
| Change, 1 year | −76.0% | −58.5% |
| Change, 5 years | −85.0% | −7.9% |
| Beta (5Y) | 1.20 | 0.49 |
| Employees | 194 | 191 |
| StockData Score | ||
| Total score | 6 | 13 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 0.8× |
| P/B | 4.4× | 0.8× (better) |
| EV/EBITDA | – | 0.5× |
| P/FCF | 2.8× | 1.5× (better) |
| FCF yield | 36.3% | 68.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.5% | 281% (better) |
| Revenue growth, 5Y average | −4.3% | 320% (better) |
| Net income growth (TTM) | – | 266% |
| Profitability | ||
| Gross margin | 79.6% | 82.8% (better) |
| Operating margin | −6.9% | 47.0% (better) |
| Net margin | −13.5% | 40.5% (better) |
| FCF margin | 18.4% | 54.2% (better) |
| Return on equity | −109% | 54.9% (better) |
| Return on invested capital | – | 171% |
| Financial health | ||
| Debt / equity | 1.98 (better) | 0.00 |
| Current ratio | 1.43 | 2.56 (better) |
| Altman Z-score | −5.89 | 2.01 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.28% |
| Shareholder yield | 0.00% (better) | −0.28% |
| Ownership | ||
| Held by institutions | 39.7% | 56.5% |
| Held by insiders | 2.9% | 3.3% |
| Insider net buying, 12 months | −$876K (better) | −$1.6M |
| Short interest, % of float | 10.1% | 18.8% |
Go deeper
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
- CRMD stock overview
- CRMD income statement
- CRMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.